Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 31, 2023
Distillery Therapeutics

PD-L1-targeting CAR-NK cells for solid tumors

BioCentury | Jan 28, 2023
Discovery & Translation

CRISPR knockdown tech from Doudna lab; plus CAR Ts for myasthenia gravis and more

BioCentury’s roundup of translational news
BioCentury | Jul 15, 2022
Distillery Therapeutics

Targeting uPAR for diffuse-type gastric cancer

BioCentury | Apr 1, 2022
Distillery Therapeutics

CDH17-targeting CAR T cells for solid tumors

BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

A roundup of clinical trial readouts for CD47 blockers, allogeneic CAR T cells and sickle cell disease
BioCentury | Nov 12, 2020
Product Development

Lining up allogeneic CAR Ts at ASH: Data Byte

Promising efficacy data from China’s Bioheng are among the allogeneic CAR T cell updates at ASH this year.  The past year has seen a growing number of clinical readouts for off-the-shelf
BioCentury | Apr 5, 2019
Tools & Techniques

Second shot for shRNA

How tool developers and CAR T cell companies could recharge shRNA therapies
BioCentury | Dec 17, 2018
Preclinical News

Downshifting CARs for better mileage

BioCentury | Jun 28, 2018
Translation in Brief

Synchronous signaling

How altering receptor motifs in CAR Ts could lead to more efficient signaling
Items per page:
1 - 10 of 20
Help Center
Username
Request a Demo
Request Training
Ask a Question